Roles of resveratrol and other grape-derived polyphenols in Alzheimer's disease prevention and treatment

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1852, Issue 6, 2014, Pages 1202-1208

  Pasinetti, Giulio Maria ^a,b   Wang, Jun ^a,b   Ho, Lap ^a,b   Zhao, Wei ^a,b   Dubner, Lauren ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Alzheimer's disease; Polyphenol; Resveratrol; SIRT1

Indexed keywords

AMYLOID; POLYPHENOL; RESVERATROL; STILBENE DERIVATIVE;

ALZHEIMER DISEASE; ANIMAL; CHEMISTRY; DRUG EFFECTS; HUMAN; METABOLISM; PATIENT EDUCATION; VITIS;

ALZHEIMER DISEASE; AMYLOID; ANIMALS; HUMANS; POLYPHENOLS; STILBENES; VITIS;

EID: 85003047354     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2014.10.006     Document Type: Review

References (83)

1. Abd El-Mohsen M., et al. Distribution of [3H]trans-resveratrol in rat tissues following oral administration. Br. J. Nutr. 2006, 96(1):62-70.
2. Abraham J., Johnson R.W. Consuming a diet supplemented with resveratrol reduced infection-related neuroinflammation and deficits in working memory in aged mice. Rejuvenation Res. 2009, 12(6):445-453.
3. Abraham T.M., Fox C.S. Implications of rising prediabetes prevalence. Diabetes Care 2013, 36(8):2139-2141.
4. ACCORD Study Group, et al Long-term effects of intensive glucose lowering on cardiovascular outcomes. N. Engl. J. Med. 2011, 364(9):818-828.
5. Albert M.S., et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011, 7(3):270-279.
6. Baur J.A., et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 2006, 444(7117):337-342.
7. Baur J.A., Sinclair D.A. Therapeutic potential of resveratrol: the in vivo evidence. Nat. Rev. Drug Discov. 2006, 5(6):493-506.
8. Beher D., et al. Resveratrol is not a direct activator of SIRT1 enzyme activity. Chem. Biol. Drug Des. 2009, 74(6):619-624.
9. Borra M.T., Smith B.C., Denu J.M. Mechanism of human SIRT1 activation by resveratrol. J. Biol. Chem. 2005, 280(17):17187-17195.
10. Burns J., et al. Plant foods and herbal sources of resveratrol. J. Agric. Food Chem. 2002, 50(11):3337-3340.
11. Cantó C., Auwerx J. Caloric restriction, SIRT1 and longevity. Trends Endocrinol. Metab. 2009, 20(7):325-331.
12. Cantó C., Auwerx J. PGC-1alpha, SIRT1 and AMPK, an energy sensing network that controls energy expenditure. Curr. Opin. Lipidol. 2009, 20(2):98-105.
13. Centers for Disease Control and Prevention National Diabetes Statistics Report: Estimates of Diabetes and Its Burden in the United States, 2014 2014, GA: US Department of Health and Human Services, Atlanta.
14. Carling D., Sanders M.J., Woods A. The regulation of AMP-activated protein kinase by upstream kinases. Int. J. Obes. (Lond.) 2008, 32(Suppl. 4):S55-S59.
15. Chaturvedi R.K., et al. Impaired PGC-1alpha function in muscle in Huntington's disease. Hum. Mol. Genet. 2009, 18(16):3048-3065.
16. Chaturvedi R.K., et al. Impairment of PGC-1alpha expression, neuropathology and hepatic steatosis in a transgenic mouse model of Huntington's disease following chronic energy deprivation. Hum. Mol. Genet. 2010, 19(16):3190-3205.
17. Citron M. Alzheimer's disease: strategies for disease modification. Nat. Rev. Drug Discov. 2010, 9(5):387-398.
18. Craft S., et al. Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial. Arch. Neurol. 2012, 69(1):29-38.
19. Dasgupta B., Milbrandt J. Resveratrol stimulates AMP kinase activity in neurons. Proc. Natl. Acad. Sci. U. S. A. 2007, 104(17):7217-7222.
20. Donmez G., Wang D., Cohen D.E., Guarente L. SIRT1 suppresses beta-amyloid production by activating the alpha-secretase gene ADAM10. Cell 2010, 142(2):320-332.
21. Farias S.T., et al. Progression of mild cognitive impairment to dementia in clinic- vs community-based cohorts. Arch. Neurol. 2009, 66(9):1151-1157.
22. Ferruzzi M.G., et al. Bioavailability of gallic acid and catechins from grape seed polyphenol extract is improved by repeated dosing in rats: implications for treatment in Alzheimer's disease. J. Alzheimers Dis. 2009, 18(1):113-124.
23. Finkel T., Deng C.X., Mostoslavsky R. Recent progress in the biology and physiology of sirtuins. Nature 2009, 460(7255):587-591.
24. 2+ and AMP. Biochem. J. 2010, 426(1):109-117.
25. Greet E.L., Brunet A. Different dietary restriction regimens extend lifespan by both independent and overlapping genetic pathways in C. elegans. Aging Cell 2009, 8(2):113-127.
26. Hardie D.G. AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. Nat. Rev. Mol. Cell Biol. 2007, 8(10):774-785.
27. Hawley S.A., et al. Use of cells expressing gamma subunit variants to identify diverse mechanisms of AMPK activation. Cell Metab. 2010, 11(6):554-565.
28. Ho D.J., et al. Resveratrol protects against peripheral deficits in a mouse model of Huntington's disease. Exp. Neurol. 2010, 225(1):74-84.
29. Ho L., et al. Heterogeneity in red wine polyphenolic contents differentially influences Alzheimer's disease-type neuropathology and cognitive deterioration. J. Alzheimers Dis. 2009, 16(1):59-72.
30. Ho L., et al. Identification of brain-targeted bioactive dietary quercetin-3-O-glucuronide as a novel intervention for Alzheimer's disease. FASEB J. 2013, 27(2):769-781.
31. Ho L., Pasinetti G.M. Polyphenolic compounds for treating neurodegenerative disorders involving protein misfolding. Expert Rev. Proteomics 2010, 7(4):579-589.
32. Ho L., Yemul S., Wang J., Pasinetti G.M. Grape seed polyphenolic extract as a potential novel therapeutic agent in tauopathies. J. Alzheimers Dis. 2009, 16(2):433-439.
33. Howells L.M., et al. Phase I randomized, double-blind pilot study of micronized resveratrol (SRT501) in patients with hepatic metastases-safety, pharmacokinetics, and pharmacodynamics. Cancer Prev. Res. 2011, 4(9):1419-1425.
34. Howitz K.T., et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 2003, 425(6954):191-196.
35. Johnson K.A., et al. Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer's disease dementia, mild cognitive impairment, and normal aging. Alzheimers Dement. 2013, 9(5 Suppl):S72-S83.
36. Karuppagounder S.S., et al. Dietary supplementation with resveratrol reduces plaque pathology in a transgenic model of Alzheimer's disease. Neurochem. Int. 2009, 54(2):111-118.
37. Krikorian R., et al. Concord grape juice supplementation improves memory function in older adults with mild cognitive impairment. Br. J. Nutr. 2010, 103(5):730-734.
38. Lagouge M., et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1α. Cell 2006, 127(6):1109-1122.
39. Launer L.J., et al. Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy. Lancet Neurol. 2011, 10(11):969-977.
40. Luchsinger J.A. Insulin resistance, type 2 diabetes, and AD: cerebrovascular disease or neurodegeneration?. Neurology 2010, 75(9):758-759.
41. MacDonald M.E., et al. The Huntington's disease candidate region exhibits many different haplotypes. Nat. Genet. 1992, 1(2):99-103.
42. Maher P., et al. ERK activation by the polyphenols fisetin and resveratrol provides neuroprotection in multiple models of Huntington's disease. Hum. Mol. Genet. 2011, 20(2):261-270.
43. Marambaud P., Zhao H., Davies P. Resveratrol promotes clearance of Alzheimer's disease amyloid-beta peptides. J. Biol. Chem. 2005, 280(45):37377-37382.
44. Mitchell A.J., Shiri-Feshki M. Rate of progression of mild cognitive impairment to dementia-meta-analysis of 41 robust inception cohort studies. Acta Psychiatr. Scand. 2009, 119(4):252-265.
45. Ono K., et al. Effects of grape seed-derived polyphenols on amyloid beta-protein self-assembly and cytotoxicity. J. Biol. Chem. 2008, 283(47):32176-32187.
46. Ono K., Naiki H., Yamada M. The development of preventives and therapeutics for Alzheimer's disease that inhibit the formation of beta-amyloid fibrils (fAbeta), as well as destabilize preformed fAbeta. Curr. Pharm. Des. 2006, 12(33):4357-4375.
47. Orgogozo J.M., et al. Wine consumption and dementia in the elderly: a prospective community study in the Bordeaux area. Rev. Neurol. (Paris) 1997, 153(3):185-192.
48. Pacholec M., et al. SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1. J. Biol. Chem. 2010, 285(11):8340-8351.
49. Pasinetti G.M., et al. Neuroprotective and metabolic effects of resveratrol: therapeutic implications for Huntington's disease and other neurodegenerative disorders. Exp. Neurol. 2011, 232(1):1-6.
50. Petersen R.C. Mild cognitive impairment as a diagnostic entity. J. Intern. Med. 2004, 256(3):183-194.
51. Poulsen M.M., et al. Resveratrol in metabolic health: an overview of the current evidence and perspectives. Ann. N. Y. Acad. Sci. 2013, 74-82.
52. Qin W., et al. Calorie restriction attenuates Alzheimer's disease type brain amyloidosis in Squirrel monkeys (Saimiri sciureus). J. Alzheimers Dis. 2006, 10(4):417-422.
53. Qin W., et al. Neuronal SIRT1 activation as a novel mechanism underlying the prevention of Alzheimer disease amyloid neuropathology by calorie restriction. J. Biol. Chem. 2006, 281(31):21745-21754.
54. Ranney A., Petro M.S. Resveratrol protects spatial learning in middle-aged C57BL/6 mice from effects of ethanol. Behav. Pharmacol. 2009, 20(4):330-336.
55. Raschetti R., Albanese E., Vanacore N., Maggini M. Cholinesterase inhibitors in mild cognitive impairment: a systematic review of randomised trials. PLoS Med. 2007, 4(11):e338.
56. Reger M.A., et al. Intranasal insulin improves cognition and modulates beta-amyloid in early AD. Neurology 2008, 70(6):440-448.
57. Rimando A.M., et al. Resveratrol, pterostilbene, and piceatannol in vaccinium berries. J. Agric. Food Chem. 2004, 52(15):4713-4719.
58. Rocha-González H.I., Ambriz-Tututi M., Granados-Soto V. Resveratrol: a natural compound with pharmacological potential in neurodegenerative diseases. CNS Neurosci. Ther. 2008, 14(3):234-247.
59. Ruderman N.B., et al. AMPK and SIRT1: a long-standing partnership?. Am. J. Physiol. Endocrinol. Metab. 2010, 298(4):751-760.
60. Sanders T.H., McMichael R.J., Hendrix K.W. Occurrence of resveratrol in edible peanuts. J. Agric. Food Chem. 2000, 48(4):1243-1246.
61. Selkoe D.J. Presenilin, Notch, and the genesis and treatment of Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 2001, 98(20):11039-11041.
62. Um J.H., et al. AMP-activated protein kinase-deficient mice are resistant to the metabolic effects of resveratrol. Diabetes 2010, 59(3):554-563.
63. Vinciguerra M., et al. SirT1 in muscle physiology and disease: lessons from mouse models. Dis. Model Mech. 2010, 3(6):298-303.
64. Vingtdeux V., Davies P., Dickson D.W., Marambaud P. AMPK is abnormally activated in tangle- and pre-tangle-bearing neurons in Alzheimer's disease and other tauopathies. Acta Neuropathol. 2011, 121(3):337-349.
65. Vingtdeux V., et al. Therapeutic potential of resveratrol in Alzheimer's disease. BMC Neurosci. 2008, 9(Suppl. 2):S6.
66. Vingtdeux V., et al. AMP-activated protein kinase signaling activation by resveratrol modulates amyloid-beta peptide metabolism. J. Biol. Chem. 2010, 285(12):9100-9113.
67. Viollet B., et al. Targeting the AMPK pathway for the treatment of Type 2 diabetes. Front. Biosci. (Landmark Ed.) 2009, 14:3380-3400.
68. Walle T. Bioavailability of resveratrol. Ann. N. Y. Acad. Sci. 2011, 1215:9-15.
69. Wang J., et al. Targeting multiple pathogenic mechanisms with polyphenols for the treatment of Alzheimer's disease-experimental approach and therapeutic implications. Front. Aging Neurosci. 2014, 6(42).
70. Wang J., et al. Brain-targeted proanthocyanidin metabolites for Alzheimer's disease treatment. J. Neurosci. 2012, 32(15):5144-5150.
71. Wang J., et al. The role of Sirt1: at the crossroad between promotion of longevity and protection against Alzheimer's disease neuropathology. Biochim. Biophys. Acta 2010, 1804(8):1690-1694.
72. Wang J., et al. Caloric restriction attenuates beta-amyloid neuropathology in a mouse model of Alzheimer's disease. FASEB J. 2005, 19(6):659-661.
73. Wang J., et al. Grape-derived polyphenolics prevent Abeta oligomerization and attenuate cognitive deterioration in a mouse model of Alzheimer's disease. J. Neurosci. 2008, 28(25):6388-6392.
74. Wang J., et al. Moderate consumption of Cabernet Sauvignon attenuates Abeta neuropathology in a mouse model of Alzheimer's disease. FASEB J. 2006, 20(13):2313-2320.
75. Wang J., et al. Potential application of grape derived polyphenols in Huntington's disease. Transl. Neurosci. 2010, 1(2):95-100.
76. Wang J., et al. Grape derived polyphenols attenuate tau neuropathology in a mouse model of Alzheimer's disease. J. Alzheimers Dis. 2010, 22(2):653-661.
77. Wang J., et al. Role of standardized grape polyphenol preparation as a novel treatment to improve synaptic plasticity through attenuation of features of metabolic syndrome in a mouse model. Mol. Nutr. Food Res. 2013, 57(12):2091-2102.
78. Wenzel E., Soldo T., Erbersdobler H., Somoza V. Bioactivity and metabolism of trans-resveratrol orally administered to Wistar rats. Mol. Nutr. Food Res. 2005, 49(5):482-494.
79. Weydt P., et al. Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1alpha in Huntington's disease neurodegeneration. Cell Metab. 2006, 4(5):349-362.
80. Witte A.V., Kerti L., Margulies D.S., Flöel A. Effects of resveratrol on memory performance, hippocampal functional connectivity, and glucose metabolism in healthy older adults. J. Neurosci. 2014, 34(23):7862-7870.
81. Xu W., et al. Accelerated progression from mild cognitive impairment to dementia in people with diabetes. Diabetes 2010, 59(11):2928-2935.
82. Yaffe K., et al. Diabetes, impaired fasting glucose, and development of cognitive impairment in older women. Neurology 2004, 63(4):658-663.
83. Yamamoto A., Lucas J.J., Hen R. Reversal of neuropathology and motor dysfunction in a conditional model of Huntington's disease. Cell 2000, 101(1):57-66.